WO2004103258A1 - Dispositif de mamelon - Google Patents

Dispositif de mamelon Download PDF

Info

Publication number
WO2004103258A1
WO2004103258A1 PCT/JP2004/005628 JP2004005628W WO2004103258A1 WO 2004103258 A1 WO2004103258 A1 WO 2004103258A1 JP 2004005628 W JP2004005628 W JP 2004005628W WO 2004103258 A1 WO2004103258 A1 WO 2004103258A1
Authority
WO
WIPO (PCT)
Prior art keywords
nipple
container
cap
holder
medicine
Prior art date
Application number
PCT/JP2004/005628
Other languages
English (en)
Japanese (ja)
Inventor
Masaharu Inoue
Nobuaki Takamizu
Tatsuhiko Kan
Wakoto Bukawa
Takumi Watanabe
Original Assignee
Combi Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Combi Corporation filed Critical Combi Corporation
Priority to KR1020057020898A priority Critical patent/KR101128968B1/ko
Priority to JP2005506314A priority patent/JP4472635B2/ja
Priority to EP04728413A priority patent/EP1625843A4/fr
Priority to US10/557,734 priority patent/US20070021782A1/en
Publication of WO2004103258A1 publication Critical patent/WO2004103258A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J11/00—Teats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J17/00—Baby-comforters; Teething rings
    • A61J17/001—Baby-comforters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J7/00—Devices for administering medicines orally, e.g. spoons; Pill counting devices; Arrangements for time indication or reminder for taking medicine
    • A61J7/0015—Devices specially adapted for taking medicines
    • A61J7/0053—Syringes, pipettes or oral dispensers

Definitions

  • the present invention relates to a nipple device capable of administering a medicine to an infant.
  • Such a pacifier has a mouthpiece, in which a tablet is placed in a void. Tablets are administered to infants by holding them in their mouths.
  • the tablets are placed in the vacant space of the mouthpiece, but when refilling the pacifier with tablets, the tablets must be placed in the vacant space of the mouthpiece, and the refilling operation is complicated. is there.
  • the pacifier needs to be cleaned regularly, but the pacifier is so integrated that the container cannot be cleaned. Disclosure of the invention
  • the present invention has been made in view of the above circumstances, and an object of the present invention is to provide a nipple device that can easily perform replenishment and cleaning of a medicine.
  • the present invention comprises a nipple, a nipple holder for holding the nipple, and a cap for engaging with the nipple holder, wherein a drug is filled in the cap and the nipple side is covered with a film.
  • a nipple device comprising: a nipple holder; and a rupture portion for breaking the film when the cap is engaged with the nipple holder.
  • the present invention is a nipple device characterized in that a nipple holder is provided with a liquid permeable body extending into the nipple, and a break portion of the nipple holder is formed of a projection for piercing a film.
  • the present invention is a nipple device characterized in that an external screw is provided on a nipple holder and an internal screw is provided on a cap to engage with the external screw.
  • the present invention is the nipple device, wherein the liquid permeable body is composed of a plate-like body that comes into contact with the film of the medicine container portion, and a rod-like body extending from the plate-like body toward the nipple.
  • the present invention is a nipple device characterized in that an opening is provided in a plate-shaped body of a liquid permeable body, and a projection projects from the nipple side to the medicine container section side through the opening.
  • the present invention is the nipple device characterized in that the medicine container portion is constituted by a medicine container provided in a cap.
  • the present invention is the nipple device, wherein the medicine container portion is formed of a region defined by a film in the cap.
  • the present invention provides a nipple device characterized in that the nipple holder has a communication space communicating with the inside of the nipple, and the communication space is provided on the medicine container side and is covered by a partition wall having a communication port. is there.
  • the present invention is the nipple device, wherein the rupture portion of the nipple holder is formed by an end of a partition wall.
  • the present invention is a nipple device characterized in that a one-way valve for allowing a medicine to flow from a medicine container portion to a nipple holder is provided at an opening of a partition wall.
  • the present invention includes a nipple, a nipple holder having a container storage part that holds the nipple and communicates with the nipple side, and a cap that is swingably attached to the nipple holder and covers the container storage part.
  • a nipple device characterized in that a medicine container is filled with a medicine in the container housing and a medicine container having an opening on the nipple side is arranged.
  • the present invention is a teat device characterized in that a cylindrical guide projecting toward the nipple is provided in the container storage section, and the medicine container has a spout inserted into the cylindrical guide.
  • the present invention is the nipple device, wherein the medicine container is detachable from the container storage part, and the cap is provided with an engagement rib for engaging with the cylindrical guide of the container storage part.
  • the present invention is the nipple device characterized in that the medicine container is made of a flexible material and is fixed in the container accommodating portion, and a cap is provided with a pressing portion for crushing the medicine container.
  • the present invention is the nipple device, wherein the medicine contains a xylitol component.
  • the present invention is a teat device wherein the medicament comprises a virus capture composition.
  • the present invention is the nipple device, wherein the virus-trapping composition contains, as active ingredients, a swallow-rich water extract and Z or swallow-rich enzyme-treated product.
  • FIG. 1 is a side sectional view showing a first embodiment of a nipple device according to the present invention. '
  • Figure 2 is an exploded view of the nipple device.
  • FIG. 3 is a view taken in the direction of the III line in FIG.
  • FIG. 4 is a side sectional view showing a nipple device according to a second embodiment of the present invention.
  • Figure 5 is an exploded view of the nipple device.
  • FIG. 6 is a perspective view showing a third embodiment of the nipple device according to the present invention.
  • Figure ⁇ is a partial sectional view of the nipple device.
  • FIG. 8 is a view showing a modification of the nipple device according to the present invention.
  • FIG. 9 is a view showing a modification of the nipple device according to the present invention.
  • FIG. 10 is a chart showing the results of examining the activity of the virus capturing composition to neutralize influenza virus infection.
  • FIG. 11 is a chart showing the results of examining the molecular species and content of sialic acid contained in the virus capturing composition.
  • FIG. 12 is a diagram showing the results obtained by separating the glycopeptides contained in the virus-trapping composition by SDS-PAGE and examining the binding to influenza virus.
  • FIG. 1 to 3 are views showing a nipple device according to a first embodiment of the present invention. Among them, FIG. 3 is a view taken in the direction of the line III in FIG.
  • the nipple device 10 extends from the nipple 11 to the mouth of the baby, the nipple holder 15 for holding the nipple 11, and the nipple 11 from the nipple holder 15. It has a liquid permeable body 25 and a cap 17 that engages with the nipple holder 15.
  • a drug container (drug container section) 20 filled with a liquid drug, for example, a xylitol component for preventing tooth decay.
  • the drug container 20 is covered with silver paper or resin film 21.
  • a projection 19 piercing the film 21 of the medicine container 20 is provided on the nipple holder 15.
  • the projection 19 functions as a rupture portion for breaking the film 21 when the cap 17 is engaged with the nipple holder 15.
  • the nipple 11 has a cylindrical nipple body 1 la and a plate-shaped base portion 1 lb provided at the base end of the nipple body 11.
  • the nipple main body 11a is provided with an opening 12 for supplying a drug sent through the liquid permeable body 25 to the outside.
  • the nipple holder 15 has a cylindrical portion 15a and a large-diameter portion 15b having a larger diameter than the cylindrical portion 15a.
  • the proximal end 1 lb of the nipple 1 1 is inserted into the large-diameter portion 15 b of the nipple holder 15, and the holding frame 13 is inside the large-diameter portion 15 b from outside the proximal end 1 lb. It fits in.
  • the nipple 11 is held by the nipple holder 15.
  • the medicine container 2Q is adapted to enter the cylindrical portion 15a of the nipple holder 15, and the medicine container 20 is joined to the cap 17.
  • the nipple 11 side of the medicine container 20 is covered with the film 21 as described above, and the film 21 is easily pierced and damaged by the projection 20 of the nipple holder 15.
  • the fluid permeable body 25 has the same shape as the film 21 of the medicine container 20 and has a disc-shaped plate 25 b in contact with the film 21 and a nipple 1 from the plate 25 b. And a bar 25a extending to one side.
  • the liquid permeable body 25 is made of a sponge material as a whole, and allows the medicine in the medicine container 20 to permeate the nipple 11 side.
  • the plate 26b of the liquid permeable body 25 has an opening 26 formed below the rod 25a.
  • the liquid permeable body 25 can be positioned and fixed by the nipple holder 15 by attaching the projection 19 of the nipple holder 15 to the opening 26 of the plate-like body 25b.
  • the rod-shaped body 25a of the liquid permeable body 25 preferably has the same outer shape as the inner shape of the nipple body 11a of the nipple 11, and in this case, the liquid permeable body 25 is connected to the nipple. Positioning and fixing can be performed by the body 11a.
  • the projection 19 of the nipple holder 15 is held between the cylindrical portion 15a and the large-diameter portion 15b, and the tip of the drug container 20 on the film 21 side is pointed. .
  • An outer screw 16 is provided on the outer surface of the cylindrical portion 15a of the nipple holder 15, and an inner screw 18 for engaging the outer screw 16 is provided on the inner surface of the cap 17.
  • the cylindrical portion 15a and the cap 17 may be engaged with each other by a one-touch fitting instead of screw engagement.
  • the cylindrical portion 15a of the nipple holder 15 and the cap 17 are engaged with each other in a sealed state.
  • the projection 19 of the nipple holder 15 is inserted into the opening 26 of the plate-like body 25b of the liquid permeable body 25.
  • the base end 11b of the nipple 11 is fitted into the large diameter portion 15b of the nipple holder 15, and the holding frame 13 is further fitted into the large diameter portion 15b.
  • the nipple 11 is held by the nipple holder 15.
  • a sealing material is interposed between the large-diameter portion 15. B of the nipple holder 15 and the holding frame 13.
  • the projection 19 of the nipple holder 15 is inserted into the opening 26 of the liquid permeable body 25, and the rod 25a of the liquid permeable body 25 comes into contact with the inner surface of the nipple body 11a.
  • the liquid permeable body 25 is positioned and fixed by the nipple holder 15 and the nipple 11.
  • the inner screw 18 of the cap 17 is engaged with the outer screw 16 of the nipple holder 15, and the cap 17 is fitted into the cylindrical portion 15a of the nipple holder 15.
  • a medicine container 20 is attached in advance to the cap 17 with an adhesive, and when the cap 17 is fitted into the cylindrical portion 15a of the nipple holder 15, the film of the medicine container 20 is formed. 21 is pierced by the projection 19 of the nipple holder 15 and is damaged.
  • the liquid drug (including the xylitol component) in the drug container 20 moves to the nipple 11 via the liquid permeable body 25.
  • the drug that has been transferred to the nipple 11 by the liquid permeant 25 enters the infant's mouth through the opening 12 in the nipple body 11 a, and the caries are formed by xylitol. Prevention can be achieved.
  • the cap 17 and the medicine container 20 are removed from the nipple holder 15, and a new medicine container 20 having a medicine container 20 filled with the medicine in advance is prepared.
  • a cap 17 is attached to the nipple holder 15.
  • each component can be disassembled by the reverse method to clean each component (see FIG. 2).
  • the new medicine container 20 and the cap 17 are simply attached to the nipple holder 15, which is easy and simple. Can be refilled. In addition, it is possible to easily clean each component only by disassembling each component.
  • FIGS. 4 and 5 the same parts as those in the first embodiment shown in FIGS. 1 to 3 are denoted by the same reference numerals, and detailed description is omitted.
  • the nipple device 10 is composed of a nipple 11 held by a baby, a nipple holder 15 holding the nipple 11, and a cap 17 engaged with the nipple holder 15.
  • a film 21 is provided in the cap 17.
  • an area 30 ′ defined by the film 21 is filled with a liquid drug, for example, a liquid drug containing a xylitol component for preventing tooth decay.
  • a region 30 defined by the film 21 in the cap 17 forms a medicine container portion.
  • the nipple holder 15 has a cylindrical portion 15a and a large-diameter large-diameter portion 15b provided on one side of the cylindrical portion 15a, and the other side of the cylindrical portion 15a.
  • the above mentioned partition wall 1 5c Is provided.
  • the nipple holder 15 having such a configuration has a communication space 33 communicating with the inside of the nipple 11 therein, and the communication space 33 is covered by the partition wall 15c described above.
  • a communication port 31 is provided in the partition wall 15c, and a one-way valve 32 is attached to the surface of the partition wall 15c on the side of the communication space 33 so as to open and close the communication port 31 freely. ing.
  • the one-way valve 32 allows the medicine in the region 30 to flow into the communication space 33, and the medicine in the communication space 33 cannot move to the region 30 side.
  • the base end 11b of the nipple 11 is fitted into the large-diameter portion 15b of the nipple holder 15, and the holding frame 13 is further inserted into the large-diameter portion 15b.
  • the nipple 11 is held by the nipple holder 15.
  • the inner screw 18 of the cap 17 is engaged with the outer screw 16 of the nipple holder 15, and the cap 17 is fitted into the cylindrical portion 15a of the nipple holder 15.
  • the region 30 defined by the film 21 in the cap 17 is filled with a drug in advance, and when the cap 17 is fitted into the cylindrical portion 15a of the nipple holder 15, The film 21 in 17 is broken by the end 15 d of the partition wall 15 c of the nipple holder 15.
  • the medicine in the area 30 flows into the communication space 33 of the nipple holder 15 through the communication port 31 and the one-way valve 32, and then the medicine in the communication space 33 is removed. Move to nipple 1 1 side.
  • the drug that has migrated to the nipple 11 enters the infant's mouth through the opening 12 and the xylitol component can prevent tooth decay.
  • the cap 17 is removed from the nipple holder 15 and a new cap 17 prefilled with the medicine is placed on the nipple holder 15. Mounted. .
  • each component is disassembled by the reverse method, and each component is cleaned (see FIG. 5).
  • the cleaning operation can be easily performed by disassembling the respective constituent members.
  • the nipple device 10 is a nipple holder 1 having a nipple 11 held by a baby and a container storage portion 33 holding the nipple 11 and communicating with the nipple 11 side. 5 and a cap 42 that is swingably attached to the nipple holder 15 and covers the container storage section 43.
  • the nipple 11 has a hollow shape, and a fluid drug filled in the drug container 45, for example, a drug containing a xylitol component for preventing tooth decay is sent and stored therein, as described later. .
  • the nipple 11 is provided with an opening 12 for supplying the drug stored therein to the outside.
  • the nipple holder 15 has a flange 40 for holding the nipple 11 and a flange cover 41 provided on the flange 40, and the container storage portion 43 is provided in the flange cover 41. ing.
  • the container storage section 43 provided on the flange cover 41 has an upper opening, and a medicine container 45 filled with a liquid drug is stored in the container storage section 43.
  • the container storage section 43 is provided with a cylindrical guide 11 protruding toward the nipple 11, and the container storage section 43 communicates with the nipple 11 via the cylindrical guide 44.
  • the cap 42 is swingably attached to the flange cover 41 of the nipple holder 15 via the driving shaft 42a so as to cover the container housing portion 43 from above.
  • An engagement rib 48 is provided on the inner surface of the cap 42 to engage with the upper end of the cylindrical guide 44. When the container 42 is covered by the cap 42, the engaging rib 48 is inserted into the container 43 and engaged with the upper end of the cylindrical guide 44.
  • the upper end of the cylindrical guide 44 has a tapered shape tapering downward, and the tip 48 a of the engaging rib 48 corresponds to the upper end of the cylindrical guide 44. It has a tapered shape that tapers downward.
  • the engagement rib 48 is made of a flexible material.
  • the inside of the medicine container 45 is filled with a liquid medicine, and the medicine is detachably stored in the container storage part 43. That is, the medicine container 45 is made of a flexible material as a whole, and has a container body 45a for accommodating a medicine and a spout 46 made of a hard material provided at the lower end of the container body 45a. are doing.
  • the spout 46 of the medicine container 45 has an external thread 46a formed on the outer surface thereof.
  • the spout 46 has an external thread 46a inside the cylindrical guide 44 of the nipple holder 15. It is inserted by screwing into the inner screw (not shown) of 4.
  • the spout 46 may be fitted into the cylindrical guide 44 without forming an external thread on the outer surface of the spout 46. .
  • the medicine container 45 before use, first remove the cover 47 screwed into the spout 46 of the medicine container 45, and remove the medicine container 45 from the container storage section 43 of the nipple holder 15. To be stored.
  • the medicine container 45 is firmly fixed in the container storage portion 43 by screwing the external screw 46 a of the spout 46 of the medicine container 45 into the inner screw of the cylindrical guide 45. it can.
  • the container body 45 a made of a flexible material of the medicine container 45 is pressed upward and pressed, and the medicine in the container body 45 a is supplied to the nipple 11 side via the spout 46 and the cylindrical guide 44. I do.
  • the medicine container 45 is removed from the container storage section 43, the cap 42 is swung via the drive shaft 42 a, and the container storage section 43 is sealed by the cap 42.
  • the engaging rib 48 provided on the inner surface of the cap 42 engages with the upper end of the cylindrical guide 44 to completely seal the upper end of the cylindrical guide 44.
  • the engaging rib 48 is entirely made of a flexible material, the upper end of the cylindrical guide 44 can be reliably sealed by the tip 48 a of the engaging rib 48.
  • the medicine in the nipple 11 enters the infant's mouth from the dent 12 of the nipple 11, and can prevent tooth decay by the xylitol component.
  • the medicine container 45 has a container body 45 a made of a bristle-like flexible material filled with a medicine, and a spout 46 provided at the lower end of the container body 45. ing.
  • the nipple holder 15 for holding the nipple 11 has a flange 40 and a container storage section 43 provided on the flange 40.
  • the container storage section 43 accommodates a medicine container 45 therein, and a cylindrical guide 44 protruding toward the nipple 11 is provided at a lower portion of the container storage section 43.
  • the container storage portion 43 has an upper opening, and a cap 42 for covering the storage portion 43 is movably attached to the container storage portion 43. Further, on the inner surface of the cap 42, a pressing portion 49 for pressing the bellows-like container body 45a is provided.
  • the medicine container 45 is accommodated in the container accommodating portion 43 of the nipple holder 15, and at the same time, the spout 46 of the medicine container 45 is inserted into the cylindrical guide 44.
  • an external thread is formed on the outer surface of the spout 46 of the medicine container 35, and an internal thread is formed on the inner surface of the cylindrical guide 44, so that the spout 46 is screwed into the cylindrical guide 44 to thereby dispens the medicine.
  • the container 45 can be firmly fixed to the container storage section 43.
  • the cap 42 is swung to cover the container storage section 43 with the cap 42.
  • the container body 45a of the medicine container 45 is pressed by the pressing portion 49 of the cap 42, and the medicine in the container body 45a passes through the spout 46 and the cylindrical guide 44 and the nipple 1 Sent to one side.
  • the medicine container 45 has a medicine container-filled container body 45a and a spout 46 provided at the lower end of the container body 45.
  • the container body 45a is not in the shape of a bellows, has a thin shape, and is made of a flexible material.
  • the medicine container 45 is stored in the container storage section 43 of the nipple holder 15.
  • an external thread may be formed in the spout 46 of the medicine container 45
  • an internal thread may be formed in the cylindrical guide 44
  • the spout 46 may be screwed into the cylindrical guide 44.
  • the cap 42 is swung to cover the container storage section 43 with the cap 42,
  • the container body 45 a of the medicine container 45 is pressed by the pressing portion 49.
  • the medicine in the container body 45 can be sent to the nipple 1 ljlj via the spout 46 and the cylindrical guide 44.
  • FIGS. 10 to 12 is different from the embodiment shown in FIGS. 1 to 12 only in that a drug containing a virus capturing composition is used instead of a drug containing a xylitol component as a liquid drug. This is substantially the same as the embodiment shown in FIG.
  • the drug containing the virus capturing composition is filled in the drug container 20 shown in FIGS. 1 to 3, and the region 17 of the cap 17 shown in FIGS. 4 and 5 is filled. Within 0, the drug containing the virus capture composition is filled instead of the drug containing the xylitol component. Further, the medicine container 45 shown in FIGS. 6 to 9 is filled with a medicine containing a virus-trapping composition instead of a medicine containing a xylitol component.
  • the virus-trapping composition contains, as active ingredients, a water extract of swallow fossa and an enzyme-treated product of fossil or swallow fossil.
  • swallow fossils are nests that make swallows their own saliva into filaments, and have been eaten as a high-quality ingredient in China for a long time, as well as for lung disease, healthy stomach, expectorant, skin rejuvenation, and tonic nutrition. It is also used as a food with medical effects. Its components are high in protein and carbohydrates, and almost free of lipids.
  • swallow fossils include those collected in natural caves (cave nest) and those cultured indoors (house nest), both of which can be used.
  • various types from those that only remove dirt such as hair and feces from the collected swallow fossils and those that are washed, and those that collect the swallow fossils and form them by repeating bleaching and washing. It is preferable to use swallow fossa that has not been washed or bleached.
  • the swallow fossil water extract of the present invention can be obtained, for example, as follows.
  • a swallow fossa crushed to a size of 2 mm or less, preferably 150 zm or less After adding 0 to 100 times the amount of water and extracting the mixture by standing or stirring at 1 to 100 ° C. for 0.5 to 48 hours, the mixture is filtered to obtain a filtrate.
  • the filtrate may be used as it is or may be appropriately concentrated to obtain a concentrated solution, which can be used as the virus capturing composition of the present invention. These may be freeze-dried or spray-dried to be powdered.
  • the enzyme-treated product of the swallow fossa was extracted by adding water or hot water in an amount of 10 to 10,000 times its mass to the swallow fossil crushed to the same size as above and extracting it in the same manner as above.
  • the solution (the solution before filtration), the filtrate obtained by filtering the extract, or the solution obtained by heat-treating the extract at 60 to 130 ° C. for 5 to 30 minutes can be obtained by enzyme treatment.
  • protease is preferable, and for example, one that is commercially available as an enzyme for food can be used alone or in combination of two or more.
  • protease is preferable, and for example, one that is commercially available as an enzyme for food can be used alone or in combination of two or more.
  • “Pancreatin F” (trade name, manufactured by Amano Pharmaceutical Co., Ltd.)
  • “Aloase AP-10” (trade name, manufactured by Yakult Yakuhin Kogyo)
  • Paper Japanese Patent Application Laid
  • Heat-resistant Proteaze Samoa trade name, manufactured by Daiwa Kasei
  • the conditions for the enzyme treatment are not particularly limited, and the pH of the solution is adjusted to the optimal pH of the enzyme to be used, an appropriate amount of the enzyme is added, and the mixture is reacted at the optimal temperature of the enzyme for 0.5 to 24 hours. Thereafter, the enzyme may be inactivated by heat treatment or the like.
  • the filtrate obtained by filtering this reaction solution can be used as it is, or can be appropriately concentrated to obtain a concentrated solution, which can be used as the virus capturing composition of the present invention. Further, these may be freeze-dried or spray-dried to be powdered.
  • the average molecular weight of the enzyme-treated product is preferably 500 to 200,000, more preferably 20,000 to 70,000.
  • the virus-trapping composition of the present invention comprises, in addition to the swallow fossil water extract obtained as described above or an enzyme-treated product thereof, functional food materials such as various sugars, lactic acid bacteria, bifidobacteria, polyphenols, and oligosaccharides; It can contain ingredients such as proteins, fatty acids, minerals, vitamins, dietary fiber, sugar alcohols, surfactants, and preservatives.
  • the form of the virus capturing agent of the present invention is not particularly limited, but is preferably a solution or a jelly.
  • the virus-trapping composition is a food-derived component, and therefore has high safety, and can be directly used on the human body as an inhalant or the like.
  • the content of the water extract of swallow fossa and / or enzymatically treated swallow fossil in the virus-trapping composition of the present invention is preferably 0.1 to 10 000 zg / mL, more preferably 0.2 400 zg / mL.
  • LDH lactate dehydrogenase
  • L 00TCID 50 50% Tissue-Culuture Infectious Dose 50% tissue culture infectious dose
  • influenza virus A / PR / 8/34 (H1N1) or A / Aichi / 2/68 (H3N2)
  • An EMEM medium Esagles Minimum Essential Medium containing each sample shown in Table 1 (final concentration 15000 1g / mL) was inoculated into monolayer cultured MDCK cells in a 96-well Thai Yuichi plate (flat bottom). 5 hours at 5 ° C Cultured.
  • LDH activity was determined by measuring the absorbance at 550 nm (control: 630 nm). Fetuin was used as a positive control. Fetuin is a component contained in fetal bovine serum and is known to have influenza neutralizing activity. Fig. 10 shows the results.
  • the IC 50 for human influenza virus of sample 1 (A / PR / 8/34 (H1N1) and A / Aichi / 2/68 (H3N2)) was SO jug / mL, indicating that the inhibitory activity was 2 to 8 times stronger than that of fetuin used as a positive control.
  • Sample 2 had almost the same inhibitory activity against human influenza virus (A / PR / 8/34 (H1N1)) as that of fein. '
  • the 25 / L in the first row was transferred to the second row, and aspirated and discharged several times with a micropipette. This operation was performed in the same manner as the third and fourth rows to prepare a two-fold dilution series.
  • the plate was gently shaken in the evening, and then left at 4 ° C for 6 ° C. Then, 0.5% (V / V) human erythrocyte suspension was dispensed into each well by 5 and the evening
  • sample 1 was tested against influenza viruses tested (viruses isolated from humans, birds and birds) except for A / Swine / Colorado / 1/77 (H3N2). It can be seen that hemagglutination is inhibited at very low concentrations. On the other hand, it can be seen that Sample 2 exhibits hemagglutination inhibitory activity at a low concentration against viruses other than A / Memphis / 1/71 and A / Swine / Colorado / 1/77 (H3N2). From the above results, it was found that Samples 1 and 2 had the ability to adsorb a wide variety of influenza viruses.
  • each sample was heated in 20 L of 2 M acetic acid at 80 C for 3 hours to hydrolyze the glycoside bonds of sialic acid, and then the fluorescent reagent (Sodium hydrosulfate 15.7 mg, 2-mercaptoethanol 350 / L and 20 / L of diamino4,5-methylenedioxybenzene 2HC1 (hereinafter referred to as DMB, Dojin Chemical Co., Ltd., adjusted to 5 mL with water) was added, and heated at 50 ° C for 2.5 hours in the dark.
  • DMB diamino4,5-methylenedioxybenzene 2HC1
  • Fig. 11 shows the results.
  • both Sample 1 and Sample 2 contained sialic acid, and N-acetylneuraminic acid (NeuAc) was found to be the major molecular species.
  • N-glycolylylamic acid (NeuGc) was also contained although the ratio was small.
  • N-acetylneuraminic acid content (12.5%) of sample 1 was about twice as high as that of sample 2 (6.52%), and the N-glycolylylamic acid content was The value was 0.41% for sample 1 and 0.09% for sample 2.
  • sialic acid contained in sample 2 is very similar to human sialic acid species, and that proteins, peptides or lipid molecules containing these sialic acids are components that bind to influenza virus.
  • sample 1 showed higher influenza virus binding activity and infection inhibitory activity than sample 2, but this fact is well correlated with the fact that sample 1 has a higher sialic acid content than sample 2. This also suggests that the sialic acid-containing molecules in the sample have anti-influenza activity.
  • SDS-PAGE sample preparation buffer 2% SDS, 10% glycerin, 0.001% Bromphenol Blue, containing 0%. 0625M Tris buffer, pH 6.8, Each sample was treated in a boiling water bath for 5 minutes. Under non-reducing conditions, 10-20% SDS-polyacrylamide (SDS-PAGE plate: trade name "ET-1020L", manufactured by ATTO Corporation) ).
  • the glycopeptide spread on the gel was transferred to a polyvinylidene difluoride (PVDF) membrane (Daiichi Kagaku) (powered at 2 mA / cm for 30 minutes), and a 5% solution of ischemic albumin (BSA) —PBS solution ( (0.2 mL / cm) at 4 ° C for 15 hours.
  • PVDF polyvinylidene difluoride
  • BSA ischemic albumin
  • the virus suspension was removed, the PVDF membrane was washed 5 times with PBS, and an anti-influenza antibody was added thereto, followed by shaking at 4 ° C for 2 hours.
  • the antibody solution was removed, the PVDF membrane was washed 5 times with PBS, and a 0.25% BSA-PBS solution of ABC (Peroxidase) Kit (trade name, manufactured by Vector Laboratories, Inc.) of VECTASTAIN Kit was added. Shake at ° C for 2 hours.
  • the virus-trapping composition of the present invention is highly safe because it contains food-derived components as active ingredients, and has an ability to adsorb various types of viruses. Can be used as In addition, by sending the virus capturing composition from the nipple 11 of the nipple device 10 into the mouth of the baby, it is possible to prevent viral infection of the baby.

Abstract

L'invention concerne un dispositif de mamelon (10) comprenant un mamelon (11) et un corps de support de mamelon (15) servant de support au mamelon (11). Dans ce dispositif, un corps perméable au liquide (25) est monté dans le corps de support de mamelon (15) et un capuchon (17) est monté sur le corps de support de mamelon (15). Un contenant de médicaments (20) recouvert d'un film (21) est stocké dans le capuchon (17). Lorsque le capuchon (17) est monté sur le corps de support de mamelon (15), la saillie (19) du corps de support de mamelon (15) perce le film (21).
PCT/JP2004/005628 2003-05-20 2004-04-20 Dispositif de mamelon WO2004103258A1 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
KR1020057020898A KR101128968B1 (ko) 2003-05-20 2004-04-20 젖꼭지 장치
JP2005506314A JP4472635B2 (ja) 2003-05-20 2004-04-20 乳首装置
EP04728413A EP1625843A4 (fr) 2003-05-20 2004-04-20 Dispositif de mamelon
US10/557,734 US20070021782A1 (en) 2004-04-20 2004-04-20 Nipple device

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/JP2003/006286 WO2004103257A1 (fr) 2003-05-20 2003-05-20 Dispositif de tetine
JPPCT/JP03/06286 2003-05-20

Publications (1)

Publication Number Publication Date
WO2004103258A1 true WO2004103258A1 (fr) 2004-12-02

Family

ID=33463130

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/JP2003/006286 WO2004103257A1 (fr) 2003-05-20 2003-05-20 Dispositif de tetine
PCT/JP2004/005628 WO2004103258A1 (fr) 2003-05-20 2004-04-20 Dispositif de mamelon

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/JP2003/006286 WO2004103257A1 (fr) 2003-05-20 2003-05-20 Dispositif de tetine

Country Status (6)

Country Link
EP (1) EP1625843A4 (fr)
JP (1) JP4472635B2 (fr)
KR (1) KR101128968B1 (fr)
CN (1) CN100418505C (fr)
AU (1) AU2003234839A1 (fr)
WO (2) WO2004103257A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011528582A (ja) * 2008-07-23 2011-11-24 マム ベービーアーティケル ゲゼルシャフト ミット ベシュレンクテル ハフツング 乳首を備えたおしゃぶり

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8545439B2 (en) * 2009-03-10 2013-10-01 Dongguan Kidsme Industrial Limited Feeding apparatus
MX2021004948A (es) * 2018-12-27 2021-07-21 Vivolab Ab Chupon con pasaje de fluido y alojamiento intercambiable.
WO2021256975A1 (fr) 2020-06-15 2021-12-23 Vivolab Ab Sucette
SE544941C2 (en) * 2020-06-15 2023-02-07 Vivolab Ab Pacifier comprising an aerosolization device

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06508Y2 (ja) * 1987-03-05 1994-01-05 パシフイツクコンサルタンツ株式会社 割れにくく飛び散らないデザインタイル
JPH065637U (ja) * 1992-06-30 1994-01-25 鴻明 李 服薬器
JPH09226848A (ja) * 1996-02-22 1997-09-02 Nissho Corp 乳児用飲料容器

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA956606A (en) * 1970-02-02 1974-10-22 Stanley J. Koll Infant feeding package
US5123915A (en) * 1990-04-27 1992-06-23 Miller Lawrence E Medicated pacifier
JPH0423669U (fr) * 1990-06-19 1992-02-26
GB2246555A (en) * 1990-07-19 1992-02-05 Christopher George Packaging for medicine
CN2115113U (zh) * 1992-02-14 1992-09-09 任超忠 两用幼儿喂药器
GB2309966A (en) * 1996-02-07 1997-08-13 Harwill Ind Pty Ltd Teat device for administering medicaments
WO1998025572A1 (fr) * 1996-12-11 1998-06-18 Crowe D E Sucette pour nourrisson - unite d'administration de fluide
JP4233074B2 (ja) * 2000-04-24 2009-03-04 ピジョン株式会社 人工乳首
JP4023669B2 (ja) * 2001-10-23 2007-12-19 日本碍子株式会社 電気化学装置

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06508Y2 (ja) * 1987-03-05 1994-01-05 パシフイツクコンサルタンツ株式会社 割れにくく飛び散らないデザインタイル
JPH065637U (ja) * 1992-06-30 1994-01-25 鴻明 李 服薬器
JPH09226848A (ja) * 1996-02-22 1997-09-02 Nissho Corp 乳児用飲料容器

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1625843A4 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011528582A (ja) * 2008-07-23 2011-11-24 マム ベービーアーティケル ゲゼルシャフト ミット ベシュレンクテル ハフツング 乳首を備えたおしゃぶり
US8636768B2 (en) 2008-07-23 2014-01-28 Mam Babyartikel Gesellschaft M.B.H. Pacifier having a nipple

Also Published As

Publication number Publication date
JP4472635B2 (ja) 2010-06-02
WO2004103257A1 (fr) 2004-12-02
KR101128968B1 (ko) 2012-03-27
CN1791374A (zh) 2006-06-21
EP1625843A1 (fr) 2006-02-15
JPWO2004103258A1 (ja) 2006-07-20
AU2003234839A1 (en) 2004-12-13
CN100418505C (zh) 2008-09-17
EP1625843A4 (fr) 2008-01-23
KR20060010779A (ko) 2006-02-02

Similar Documents

Publication Publication Date Title
TW205035B (fr)
JP4369623B2 (ja) 体液から治療上有効なタンパク質であるインターロイキン−１受容体拮抗薬を産生するための方法
ES2249207T3 (es) Agente de supresion de la resorcion osea.
Stephen et al. Methods for collecting individual components of mixed saliva: the relevance to clinical pharmacology.
KOPPEL et al. Thiazide-lnduced Rise in Serum Calcium and Magnesium in Patients on Maintenance Hemodialysis
JP2007532416A (ja) 液状の配合物を調合するための容器
CA1232839A (fr) Ddavp antidiuretique et methode d'application
TW201216951A (en) Oral dosing device for administration of medication
US20070021782A1 (en) Nipple device
CN102405041A (zh) 包含β-阻断剂的儿科溶液
RU2478393C2 (ru) Адсорбент, моющее средство, лекарственное средство при почечной недостаточности и функциональное питание
WO2004103258A1 (fr) Dispositif de mamelon
WO2014061808A1 (fr) Composition nutritionnelle pour patients équipés d'un tube de gastrostomie
ES2252478T3 (es) Composiciones para la remocion del cerumen humano.
d’Amone et al. Stabilization of salivary biomarkers
Greene et al. A microbiological method for the determination of tryptophane
JP2005206547A (ja) ウイルス捕捉組成物、及びそれを吸着させたウイルス捕捉フィルター
KR101987754B1 (ko) 구강 질환 검사용 용기 및 이를 포함하는 검사 키트
Fabris et al. Recovery of age-related decline of thymic endocrine activity and PHA response by lysin-arginine combination
US20100324469A1 (en) Drug product, a method of administrating a vaccine using the drug product, and an apparatus for iontophoresis
AU608545B2 (en) An improved method
WO2007118292A3 (fr) PROTÉINE MEMBRANAIRE Sm29 DE SCHISTOSOMA MANSONI ET SES UTILISATIONS POUR LE TRAITEMENT ET LE DIAGNOSTIC DE LA BILHARZIOSE
Hanawalt et al. Intravenous carbohydrate tolerance tests on swine
ES2886001T3 (es) Péptido homodimérico para el tratamiento de la diabetes y enfermedades relacionadas
Hektoen et al. The use of kaolin to remove bacteria from the throat and nose

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1020057020898

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 20048136970

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 2007021782

Country of ref document: US

Ref document number: 2005506314

Country of ref document: JP

Ref document number: 10557734

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2004728413

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020057020898

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2004728413

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 10557734

Country of ref document: US